Evidence map›Paper›PMID 32476109›Full record

ArticleCancer chemotherapy and pharmacology2020

In vitro drug sensitivity (IDS) of patient-derived primary osteosarcoma cells as an early predictor of the clinical outcomes of osteosarcoma patients.

Jeerawan Klangjorhor, Areerak Phanphaisarn, Pimpisa Teeyakasem, Parunya Chaiyawat, Phichayut Phinyo, Jongkolnee Settakorn, Nipon Theera-Umpon, Dumnoensun Pruksakorn

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jeerawan KlangjorhorMusculoskeletal Science and Translational Research Center, Chiang Mai University, Chiang Mai, 50200, Thailand.
Areerak PhanphaisarnDepartment of Orthopedics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Pimpisa TeeyakasemMusculoskeletal Science and Translational Research Center, Chiang Mai University, Chiang Mai, 50200, Thailand.
Parunya ChaiyawatMusculoskeletal Science and Translational Research Center, Chiang Mai University, Chiang Mai, 50200, Thailand.
Phichayut PhinyoCenter for Clinical Epidemiology and Clinical Statistics, Faculty of Medicine, Ching Mai University, Chiang Mai, Thailand.
Jongkolnee SettakornMusculoskeletal Science and Translational Research Center, Chiang Mai University, Chiang Mai, 50200, Thailand.
Nipon Theera-UmponBiomedical Engineering Institute, Chiang Mai University, Chiang Mai, Thailand.
Dumnoensun PruksakornMusculoskeletal Science and Translational Research Center, Chiang Mai University, Chiang Mai, 50200, Thailand. dumnoensun.p@cmu.ac.th.ORCID http://orcid.org/0000-0002-5358-9336
Chiang Mai University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEarly prediction of clinical response to conventional chemotherapy is a significant factor in determining an overall treatment strategy for osteosarcoma.

methodsCells were extracted from treatment-naïve biopsies from 16 osteosarcoma patients who received a doxorubicin and cisplatin-based neoadjuvant chemotherapy regimen and their sensitivities to doxorubicin and cisplatin were measured as IC50 values. Associations of in vitro drug sensitivity (IDS) levels and clinical outcomes were examined.

resultsPrimary osteosarcoma cells responded to doxorubicin and cisplatin with IC50 values of 0.088 ± 0.032 µM and 16.7 ± 8.5 µM, respectively. The patients with a non-metastatic phenotype and surviving patients showed significantly lower IC50 values for both drugs. ROC analysis defined the optimal IC50 cut-off values for doxorubicin (IDS

conclusionsThis study indicates that IDS analysis could potentially be a practical, rapid, and reliable technique for predicting clinical outcomes. It could also be used to identify patients for whom conventional chemotherapy is most appropriate and, in the future, help advance personalized therapy.

Indexed as

Cell ProliferationAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsCase-Control StudiesChemotherapy, AdjuvantChildChild, PreschoolCisplatinCombined Modality TherapyDoxorubicinFemaleFollow-Up StudiesHumansIn Vitro TechniquesCisplatinDoxorubicinChemotherapyIC50OsteosarcomaPrecision medicinePredictive testingSurvival rate

Identifiers

PMID32476109
OpenAlexW3029902541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.